Search Results

Terry Kenakin is launching a new learning space with video courses, AMAs, and practical insights . Get a sneak peek  and sign up for The Kenakin Brief—his free weekly newslette r.   Terry Kenakin. You can already explore the platform and subscribe to The Kenakin Brief—our new newsletter packed with

Terry Kenakin invites us to challenge outdated assumptions and step into a new era of drug discovery.

Terry Kenakin , continues to grow. Kenakin. We’re fortunate to partner with Dr. Terry Kenakin , a pioneer who helped shape modern pharmacology and deepen our understanding of GPCR function

. 🔍 This Week in Premium: Sneak Peek Industry insights:  Strategic biotech alliances (Chemspace/Enamine Terry Kenakin reframes GPCRs as dynamic, allosteric sensors—far from static binding sites. To stay in the know on upcoming courses and AMA session, get the complementary Kenakin Brief , the weekly Terry Kenakin on “The Kinetics of Allostery: The Added Benefits of Allosteric Function.”

I’m honored to be chairing a session  in this track — with none other than Terry Kenakin  on the speaker Takeda   🎥 Interview with Kris Borzilleri & Alison Heick Varghese from Pfizer 🎥 Interview with Terry Kenakin at Discovery on Target Terry Kenakin’s work on functional selectivity  has transformed GPCR drug discovery Kenakin Himself If you’re part of the Dr. , you already know about Terry’s Corner  — our exclusive, on-demand pharmacology series where Terry Kenakin

Terry Kenakin reveals how drug chemistry defines function, not just fit. Kenakin. I wish Dr.

Kenakin’s answers. Kenakin  noted, it wasn’t designed. Kenakin talked about  the specific allosteric properties orthosteric drugs cannot offer. Kenakin reveals  the substrate strategy needed for credible DDI assessment. Kenakin reveals  how teams choose between slow-off and true irreversible strategies.

Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have Kenakin clarifies that both direct hepatotoxic effects and conditional toxicities, such as those driven Kenakin demonstrates how mechanistic assays allow for early warning, ensuring that compounds prone to Kenakin details how discovery teams can leverage atypical conditions to elucidate liabilities and satisfy

Kenakin’s latest lecture delivers a wake-up call for pharmacologists interpreting allosteric binding Kenakin shows how even small cooperativity values (like α = 0.1) cap the shift in signal . Kenakin lays out why this is flawed. Binding assays  report on one set of receptor states. Kenakin doesn’t just challenge assumptions. He gives you the tools to replace them . Terry Kenakin An always-growing library of on-demand pharmacology insights The ability to vote on or

Kenakin’s latest lecture delivers a game-changing framework for teams grappling with the gap between Kenakin walks you through the science, the data, and the practical methods for making it happen.   Kenakin shows how this plays out in model systems and clinical data—and why residence time should be The good news: we now have reliable, low-cost assays to find out —Kenakin walks through the essential Stay ahead with The Kenakin Brief  — a concise, science‑first email update with the latest insights in

Kenakin used those questions to explore how pharmacological reasoning turns experimental signals into Kenakin explains, pharmacology differs from other life sciences precisely because it builds quantitative Kenakin reveals how scaled pharmacological metrics allow teams to interpret receptor signaling changes Kenakin often recalls advice from Nobel laureate James Black: Chemists make the drugs. Kenakin summarizes the mindset required with a quote attributed to Winston Churchill: Success is the

Kenakin’s latest lecture delivers a paradigm shift for pharmacologists working on drugs where in vitro From restricted tissue diffusion to PK–PD dissociation, Kenakin equips you with the kinetic models and Kenakin walks through cases where two equipotent ligands produce radically different clinical outcomes But as Kenakin shows, t½ is a surface metric —a combination of clearance and volume of distribution. Kenakin offers not just theory, but tools to model, predict, and validate this behavior early.

Kenakin argues, every downstream variable becomes distorted —from preclinical modeling to dose selection Kenakin challenges the assumption that “good enough” tools guarantee progress, emphasizing that judgment Kenakin presents cases where unexpected distribution profiles forced complete strategic pivots Plasma Kenakin introduces mass-balance thinking and metabolic accounting  to proactively manage liabilities Terry Kenakin, monthly AMAs, and a growing on-demand library built around pharmacology's most important

Kenakin. Get curated content at your own pace.   Subscribe to The Kenakin Brief below to stay in the know. Terry Kenakin   Terry’s Corner is your space focused on GPCR pharmacology designed just for you.   Terry Kenakin brings translational clarity to complex receptor concepts.   Advance with nuanced lessons on allostery, residence time, and translational PK/PD   Subscribe to The Kenakin

Potency does not,” says Kenakin. Kenakin reminds us: “Allostery will seek you—even if you don’t seek it.” You must bridge that gap,” Kenakin notes. Kenakin with your own enzyme or GPCR interaction puzzles. Subscribe to The Kenakin Brief  today ➤

Kenakin’s latest   lecture delivers exclusive, real-world insight designed to equip you to move beyond Kenakin’s kinetic insights help you translate assay readouts into actionable knowledge that keeps your But as Kenakin shows in this lecture, the reality is more nuanced, and mastering drug binding kinetics Kenakin’s lecture guides you through key questions that should shape your decision-making process: Are Kenakin gives you clear, practical guidance on when to look deeper and how to extract meaningful, operational

Kenakin will address receptor theory, assay interpretation, biased signaling, and practical drug discovery ▶️ https://www.youtube.com/@TerryPharmacologyCorner New White Paper on GPCR Biased Signaling Terry Kenakin updates on future AMAs, new YouTube releases, white papers, and ongoing pharmacology insights, join Terry Kenakin

In this foundational lesson, Terry Kenakin dives deep into a widely used, often misunderstood tool in use calcium assays with strategic clarity. 📍 Foundational Level | Calcium Assays 📚 Part of Terry Kenakin

Kenakin’s latest lecture delivers high-impact insight crafted for teams navigating the complex behaviors As Kenakin explains, all GPCR signaling is allosteric , and pretending otherwise introduces risk at every Assay timing and readout design Misclassification of lead candidates Underestimation of in vivo potency Kenakin In this lecture, Kenakin lays out why no ligand binds without altering receptor conformation , and how Terry Kenakin Monthly Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to

Terry Kenakin’s session examines not just how  binding works, but why  so many datasets mislead even Kenakin stresses, the apparent simplicity collapses once biological reality intrudes. Kenakin is unequivocal: do not use them. Kenakin outlines a pragmatic checklist for producing reliable orthosteric binding measurements: Cell Kenakin demonstrates how premature stopping mis-ranks compounds, particularly when tracer and displacer

Kenakin from Terry's Corner shows how to tame irreversible drugs so their kinetic power works for you Kenakin — October 30, 12 PM EST   Join Dr. Kenakin live and bring the questions that keep you thinking. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about Kenakin… sorely needed in the field." — DrGPCR University Attendee 🚀 Join now — and learn to design

Terry Kenakin’s decades of GPCR insight. Kenakin   Four decades of receptor theory now fit in one expert-guided hub. Sign Up for The Kenakin Brief Fluorescent Ligands vs.

Terry Kenakin takes you on a captivating tour through the history of pharmacology : a journey that spans Kenakin also celebrates the giants on whose shoulders we stand—A.J.

Kenakin demonstrates in this session of Terry’s Corner, what we often measure is not receptor selectivity Kenakin reveals how two compounds tested in different systems can appear to differ by thousands-fold Kenakin uses a lever analogy where: Efficacy is the weight applied. Kenakin outlines a practical solution: use a potency metric that incorporates both efficacy and EC₅₀ Terry Kenakin, monthly live AMAs, and a growing on-demand library built for scientists who need clarity

Terry Kenakin exposes why traditional displacement logic breaks down in allosteric systems, and how overlooking Terry Kenakin on The Kinetics of Allostery . Exclusive Discount: Use code DRGPCR25  for $200 off. Kenakin is a leading expert in the field. Kenakin is a masterful teacher and communicator." — DrGPCR University Attendee The difference between

Kenakin’s Emerging Drug Hunter  lecture delivers exclusive, cutting-edge insights that help you move But as Terry Kenakin reveals, this interpretation can be misleading, and sticking with it could slow Kenakin challenges this assumption and shows that what you’re seeing may reflect something entirely different

Terry Kenakin to elevate your science and sharpen your calls. Kenakin is today, September 18th, 12-1 pm EST in Terry’s Corner. Corner members get to rewatch the recording Subscribe to the Kenakin Brief and Join the Live AMA ➤ Celtarys Kenakin is a leading expert in the field. Kenakin is a masterful teacher and communicator." — DrGPCR University Attendee Everything you need to

Kenakin dissects how P450s can be both protective and problematic. Terry Kenakin This Month’s Live AMA — October 30 at 12 PM EST Join Dr. Kenakin live for an open Q&A session designed for discovery scientists. Kenakin with your own enzyme or GPCR interaction puzzles. Subscribe to The Kenakin Brief  today ➤

Terry Kenakin walks through the core early assays that protect your chemistry, budget, and timeline. Kenakin takes place February 26 at 12:00 PM EST. Subscribe to the free Kenakin Brief Newsletter to join the AMA . Terry Kenakin at a significantly reduced cost. This is not commentary.

Terry Kenakin ; GIP receptor agonist patent WO2025264700. 🔍 This Week in Dr.GPCR Premium: Sneak Peek Terry Kenakin reframes PK as a predictive, manageable discipline , not an unavoidable bottleneck. Here's how: Watch the course trailer ➤ Read the blog post ➤ Subscribe to the Kenakin Brief ➤ Dr.